EYENOVIA INC (EYEN) Stock Overview
USA - NASDAQ:EYEN - US30234E2037 - Common Stock
EYEN Key Statistics, Chart & Performance
The current stock price of EYEN is 15.82 USD. In the past month the price increased by 649.76%. In the past year, price decreased by -77.32%.
EYEN Latest News, Press Relases and Analysis
EYEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 14.34 | 125.85B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| GSK | GSK PLC-SPON ADR | 9.67 | 86.97B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
Related stock screener links
About EYEN
Company Profile
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
Company Info
EYENOVIA INC
295 Madison Ave Ste 2400
New York City NEW YORK 10017 US
CEO: Tsontcho Ianchulev
Employees: 14
Phone: 18137669539
EYENOVIA INC / EYEN FAQ
Can you describe the business of EYENOVIA INC?
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
What is the current price of EYEN stock?
The current stock price of EYEN is 15.82 USD. The price increased by 49.81% in the last trading session.
Does EYEN stock pay dividends?
EYEN does not pay a dividend.
What is the ChartMill technical and fundamental rating of EYEN stock?
EYEN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is EYEN stock listed?
EYEN stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of EYEN stock?
EYENOVIA INC (EYEN) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for EYENOVIA INC?
EYENOVIA INC (EYEN) will report earnings on 2025-08-11, after the market close.
EYEN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EYEN. When comparing the yearly performance of all stocks, EYEN is one of the better performing stocks in the market, outperforming 99.78% of all stocks.
EYEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EYEN. EYEN may be in some trouble as it scores bad on both profitability and health.
EYEN Financial Highlights
Over the last trailing twelve months EYEN reported a non-GAAP Earnings per Share(EPS) of -34.16. The EPS increased by 43.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -708.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EYEN Forecast & Estimates
8 analysts have analysed EYEN and the average price target is 163.2 USD. This implies a price increase of 931.61% is expected in the next year compared to the current price of 15.82.
For the next year, analysts expect an EPS growth of 33.51% and a revenue growth 400.98% for EYEN